iC9-CAR.B7-H3 T Cell Therapy

Phase 1

UUNC Lineberger Comprehensive Cancer Center

iC9-CAR.B7-H3 T Cell Therapy is one of 26 therapeutic programs targeting Breast Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Breast CancerRecruiting

Breast CancerPhase 1

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lexiscan

Astellas

Preclinical

1 2

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 3

Vfend

PPrism Pharmaceuticals

Preclinical

—4

Ablavar

LLantheus Medical Imaging

Preclinical

2 5

iC9-CAR.B7-H3 T Cell Therapy

UUNC Lineberger Comprehensive Cancer Center

Phase 1

1 6

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 7

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

1 9

Ibrance

Pfizer

Preclinical

1 10

Fluorothymidine F-18

MM.D. Anderson Cancer Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 1Recruiting

Breast Cancer

NCT06347068

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Study of Administration of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors and Containing the Inducible Caspase 9 Safety Switch in Subjects With Triple Negative Breast Cancer

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT06347068·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for iC9-CAR.B7-H3 T Cell Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for iC9-CAR.B7-H3 T Cell Therapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — UNC Lineberger Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: UUNC Lineberger Comprehensive Cancer Center

iC9-CAR.B7-H3 T Cell Therapy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News